Publication:
Evidence that PKC? inhibition in Dalton's Lymphoma cells augments cell cycle arrest and mitochondrial-dependent apoptosis

Simple item page
dc.contributor.authorSingh, Rishi Kant
dc.contributor.authorVerma, Praveen Kumar
dc.contributor.authorKumar, Sandeep
dc.contributor.authorShukla, Alok
dc.contributor.authorKumar, Naveen
dc.contributor.authorKumar, Sanjay
dc.contributor.authorAcharya, Arbind
dc.date.accessioned2025-01-27T10:09:52Z
dc.date.available2025-01-27T10:09:52Z
dc.date.issued2022
dc.description.abstractProtein kinase C? (PKC?), belonging to ser/thr protein kinase, perform various biological functions. Overexpression of PKC? has been observed in multiple human malignancies including lymphoma. However, the molecular pathogenesis and involvement of PKC? in Non-Hodgkin lymphoma (NHL) are not clearly understood. Hence, deciphering the role of PKC? in NHL management may provide a better therapeutic option. In the present study, we used selective pharmacological inhibitors G�6976 and Ro320432 that potentially inhibit PKC?-mediated signaling in DL cells, resulting in the inhibition of cell growth and mitochondrial-dependent apoptosis. PKC? inhibition by these inhibitors also displays cell cycle arrest at the G1 phase and causes growth retardation of DL cells. Our results extended the mechanism of PKC? in NHL, and provided potential implications for its therapy. � 2022 Elsevier Ltd
dc.identifier.doihttps://doi.org/10.1016/j.leukres.2021.106772
dc.identifier.issn1452126
dc.identifier.urihttps://dl.bhu.ac.in/ir/handle/123456789/14282
dc.publisherElsevier Ltd
dc.subjectApoptosis
dc.subjectCell cycle
dc.subjectDalton's Lymphoma cells
dc.subjectNon-Hodgkin lymphoma
dc.subjectProtein kinase C-?
dc.titleEvidence that PKC? inhibition in Dalton's Lymphoma cells augments cell cycle arrest and mitochondrial-dependent apoptosis
dc.typeArticle
dspace.entity.typePublication
journal.titleLeukemia Research
journalvolume.identifier.volume113

Files

Collections

2022